Results 71 to 80 of about 56,993 (185)

Severe hypoproteinemia caused by sevelamer hydrochloride in a hemodialysis patient

Nihon Toseki Igakkai Zasshi, 2007
症例は73歳, 男性. 2002年4月より腎硬化症による慢性腎不全で血液透析導入. リン吸着目的に塩酸セベラマーを2004年8月31日より1日3g内服を開始した. 内服1か月後より血中タンパク濃度が急速に低下した. 3か月後に内服量を半減するも, 半年後には血清総タンパク濃度3.7g/dL, アルブミン濃度2.1g/dLと著明な低タンパク血症をきたしたため内服中止した. 中止後血中タンパク濃度が元のレベルに改善するのに約半年を要した. 低タンパク血症の原因にタンパク摂取低下の可能性はあるが, 症例は自己管理良好で食事摂取量や体重, 貧血に変化はなくタンパク摂取不足による栄養障害は主因でないと考えられた.
Sakai, Syoji, Sasaki, Tsuyoshi, Matsumoto, Takafumi, Saito, Yasuhiro, Kasuga, Shumon, Okuda, Seiya   +5 more
openaire   +2 more sources

Bias in spontaneous reporting of adverse drug reactions in Japan.

PLoS ONE, 2015
BackgroundAttitudes of healthcare professionals regarding spontaneous reporting of adverse drug reactions (ADRs) in Japan are not well known, and Japan's unique system of surveillance, called early post-marketing phase vigilance (EPPV), may affect these ...
Shinichi Matsuda, Kotonari Aoki, Takuya Kawamata, Tetsuji Kimotsuki, Takumi Kobayashi, Hiroshi Kuriki, Terumi Nakayama, Seigo Okugawa, Yoshihiko Sugimura, Minami Tomita, Yoichiro Takahashi   +10 more
doaj   +1 more source

Effect of Sevelamer Hydrochloride Exposure on Carotid Intima Media Thickness in Hemodialysis Patients

, 2010
<i>Background:</i> Elevated phosphorus (P) and calcium (Ca)-P product (Ca × P) are associated with vascular calcification and cardiovascular disease (CVD) morbidity and CVD and all-cause mortality.
D. Schwartz, A. Biro, M. Boaz, Z. Katzir, G. Chernin, T. Weinstein, U. Gafter, V. Kon, L. Shtendik   +8 more
core   +1 more source

Sevelamer and Other Anion-Exchange Resins in the Prevention and Treatment of Hyperphosphataemia in Chronic Renal Failure

, 2007
Sevelamer, or more precisely ‘sevelamer hydrochloride’, is a weakly basic anion-exchange resin in the chloride form that was introduced in 1997 for the treatment of the hyperphosphataemia of patients with end-stage renal failure, usually those on long ...
Clive Harland, Oliver Wrong
core   +1 more source

Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels [PDF]

Background: In hemodialysis patients, adynamic bone disease has been reported to be closely associated with low levels of parathyroid hormone (PTH) due to exposure to high levels of serum calcium following the administration of calcium carbonate (CaCO3 ...
Takaeda, Masayoshi, Okumura, Toshiya, Yoshimoto, Keiichi, Furuichi, Kengo, Yokoyama, Hitoshi, Shimizu, Kazuaki, Nakaya, Izaya, Ohta, Satoshi, Kokubo, Satoshi, Takasawa, Kazuya, Yamahana, Junya, Koshino, Yoshitaka, Takeda, Shinichi, Wada, Takashi, Kobayashi, Motoo, Toyama, Tadashi, Iwata, Yasunori, Kitagawa, Kiyoki, Kitajima, Shinji, Sakai, Norihiko, Kaneko, Shuichi, Hara, Akinori, Takaeda, Chikako   +22 more
core   +2 more sources

A Retrospective Single-Center Study of Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Children With Tumor Lysis Syndrome. [PDF]

Cureus, 2023
Al Blewi SM, AlAzmi AA, Elimam N, Jastaniah W, Mohammedkhalil A, Abdullah S.   +5 more
europepmc   +1 more source

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study

, 2010
Background. Cardiovascular morbidity and mortality are massively increased in patients with chronic kidney disease (CKD). Sevelamer hydrochloride has been shown to attenuate cardiovascular calcifications in CKD and end-stage renal disease (ESRD) patients.
Busch, Birgit, Vanholder, Raymond, Meert, Natalie, Schlieper, Georg, Brandenburg, Vincent Matthias, Holzmann, Stefan, Ketteler, Markus, Floege, Jürgen, Jahnen-Dechent, Willi, Meijers, Björn, Heussen, Nicole, Fassbender, Walter J, Evenepoel, Pieter   +12 more
core   +1 more source

EVALUATION OF THE EFFECTS OF SEVELAMER HYDROCHLORIDE IN MINERAL AND BONE METABOLISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5D

, 2018
Objetivo: Evaluar los efectos del clorhidrato de sevelamer en el metabolismo mineral y óseo en pacientes con enfermedad renal crónica estadio 5D en hemodiálisis.
Martinez Aguilar, Louis Antonio
core   +1 more source

Prospective observational study of sevelamer hydrochloride and lanthanum carbonate-Effect of sevelamer hydrochloride on the acid-base equilibrium of patients on hemodialysis with citric acid dialysate

Nihon Toseki Igakkai Zasshi, 2010
血液透析患者の代謝性アシドーシス状態の持続は入院頻度の増加や生命予後の悪化につながり，骨代謝に対して悪影響を与えることも報告されている．今回われわれは，重炭酸を多く含むクエン酸透析液（カーボスター®）を使用した血液透析時に，リン（P）吸着剤の塩酸セベラマー：SHと炭酸ランタン：LCを用いた前向き観察研究を行い，両P吸着剤が血液透析患者の酸塩基平衡に及ぼす影響について検討した．方法：食事療法にもかかわらずSHを多く（≧5,250 mg/日）内服する患者40名を20名ずつランダムにSH群とLC群の2群に分けた．それぞれのP吸着剤を5週間内服し，その後両群ともSHを4週間内服した．結果：両群ともベースラインにおいてクエン酸透析液の使用にもかかわらず強い代謝性アシドーシス（HCO3－≦20 mEq/L ...
Matsushita, Kazumichi, Tabata, Hidehiro, Nitta, Kosaku, Tago, Kiichiro   +3 more
openaire   +2 more sources

Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate

Therapeutics and Clinical Risk Management, 2008
Ismail A Mohammed, Alastair J HutchisonManchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Oxford Road, Manchester, UKAbstract: Hyperphosphatemia is an inevitable consequence of end stage chronic kidney disease and is ...
Ismail A Mohammed, Alastair J Hutchison
doaj